Reduced Fibrinolysis Links Obesity to Cardiovascular Risk in Psoriasis Independently of Inflammation: A Novel Mechanistic Pathway

Yamanaka K, Yamamoto O, Honda T. Pathophysiology of psoriasis: a review. J Dermatol 2021; 48: 722–731. DOI: https://doi.org/10.1111/1346-8138.15913

Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 42: 3227–3237. DOI: https://doi.org/10.1093/eurheartj/ehab484

Gisondi P, Bellinato F, Girolomoni G, Albanesi C. Pathogenesis of chronic plaque psoriasis and its intersection with cardio-metabolic comorbidities. Front Pharmacol 2020; 25: 11. DOI: https://doi.org/10.3389/fphar.2020.00117

Wang L, Chen L, Liu Z, Liu Y, Luo M, Chen N, et al. PAI-1 exacerbates white adipose tissue dysfunction and metabolic dysregulation in high fat diet-induced obesity. Front Pharmacol 2018; 26; 9. DOI: https://doi.org/10.3389/fphar.2018.01087

Cai J, Cui L, Wang Y, Li Y, Zhang X, Shi Y. Cardiometabolic comorbidities in patients with psoriasis: focusing on risk, biological therapy, and pathogenesis. Front Pharmacol 2021; 4: 12. DOI: https://doi.org/10.3389/fphar.2021.774808

Antovic A. The overall hemostasis potential: a laboratory tool for the investigation of global hemostasis. Semin Thromb Hemost 2010; 26: 772-779. DOI: https://doi.org/10.1055/s-0030-1265294

Merzel Šabović EK, Kraner Šumenjak T, Božič Mijovski M, Janić M. Overall hemostatic potential as a marker of subclinical hypercoagulability in treated psoriasis patients. Front Med (Lausanne) 2025; 21: 12. DOI: https://doi.org/10.3389/fmed.2025.1611827

Visser MJE, Venter C, Roberts TJ, Tarr G, Pretorius E. Psoriatic disease is associated with systemic inflammation, endothelial activation, and altered haemostatic function. Sci Rep 2021; 22: 13043. DOI: https://doi.org/10.1038/s41598-021-90684-8

Visser MJE, Tarr G, Pretorius E. Thrombosis in psoriasis: cutaneous cytokine production as a potential driving force of haemostatic dysregulation and subsequent cardiovascular risk. Front Immunol 2021; 16: 12. DOI: https://doi.org/10.3389/fimmu.2021.688861

Gue YX, Ding WY, Lip GY, Gorog DA. Assessment of endogenous fibrinolysis in clinical practice using novel tests: ready for clinical roll-out? SN Appl Sci 2021; 3: 524. DOI: https://doi.org/10.1007/s42452-021-04517-4

Stark K, Massberg S. Interplay between inflammation and thrombosis in cardiovascular pathology. Nat Rev Cardiol 2021; 18: 666–682. DOI: https://doi.org/10.1038/s41569-021-00552-1

Jennewein C, Tran N, Paulus P, Ellinghaus P, Eble JA, Zacharowski K. Novel aspects of fibrin(ogen) fragments during inflammation. Mol Med 2011; 4: 568–573. DOI: https://doi.org/10.2119/molmed.2010.00146

Dehghani T, Panitch A. Endothelial cells, neutrophils and platelets: getting to the bottom of an inflammatory triangle. Open Biol 2020; 14: 10. DOI: https://doi.org/10.1098/rsob.200161

Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41: 255–323. DOI: https://doi.org/10.1093/eurheartj/ehz486

Bladbjerg EM, Stolberg CR, Juhl CB. Effects of obesity surgery on blood coagulation and fibrinolysis: a literature review. Thromb Haemost 2020; 120: 579–591. DOI: https://doi.org/10.1055/s-0040-1702224

Garg V, Verma S, Connelly K. Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes. Prog Cardiovasc Dis 2019; 62: 349–357. DOI: https://doi.org/10.1016/j.pcad.2019.07.005